We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Voluven Sales Staff Claims Draw Untitled Letter for Hospira
Voluven Sales Staff Claims Draw Untitled Letter for Hospira
February 3, 2012
A Hospira sales aid promoting Voluven for treating and preventing hypovolemia makes numerous unsubstantiated efficacy and comparative claims and downplays the drug’s risks, an FDA untitled letter states.